Market Overview

UPDATE: Oppenheimer Initiates Coverage on Neurocrine Biosciences on Potential Elagolix Success


In a report published on Tuesday, Oppenheimer analyst David Ferreiro initiated coverage on Neurocrine Biosciences (NASDAQ: NBIX) with a rating of Outperform and a price target of $16.

In the report, Oppenheimer stated, "in the ph.III endometriosis results (1H14) and the ph.IIb fibroids results (2H14). Given these blockbuster opportunities, we envisage significant upside on positive outcomes. We view secondary asset, NBI-98854, for tardive dyskinesia (TD), as risky, but believe only modest value is baked in."

Neurocrine Biosciences closed on Monday at $12.72.

Latest Ratings for NBIX

Jun 2020Goldman SachsDowngradesBuyNeutral
Jun 2020JP MorganMaintainsOverweight
Jun 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings


Related Articles (NBIX)

View Comments and Join the Discussion!

Posted-In: David Ferreiro OppenheimerAnalyst Color Initiation Analyst Ratings

Latest Ratings

ELFDA DavidsonMaintains24.0
NVDAB of A SecuritiesMaintains460.0
CBB of A SecuritiesMaintains114.0
BHCB of A SecuritiesMaintains14.0
AEEB of A SecuritiesMaintains79.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at